[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
[HTML][HTML] Adaptive immunity to SARS-CoV-2 and COVID-19
The adaptive immune system is important for control of most viral infections. The three
fundamental components of the adaptive immune system are B cells (the source of …
fundamental components of the adaptive immune system are B cells (the source of …
An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
REGEN-COV antibody combination and outcomes in outpatients with Covid-19
DM Weinreich, S Sivapalasingam… - … England Journal of …, 2021 - Mass Medical Soc
Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine
The first two mRNA vaccines against infection by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that were approved by regulators require a cold chain and …
coronavirus 2 (SARS-CoV-2) that were approved by regulators require a cold chain and …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
[HTML][HTML] SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …